Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma

肾损伤分子 1 (KIM-1) 作为肾细胞癌生物标志物的临床特征

• 批准号: 10365631
• 负责人: David McDermott
• 金额: $ 45.42万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-12-15 至 2026-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10365631
• 关键词: Address; Adjuvant; Adjuvant Study; Adjuvant Therapy; Angiomyolipoma; BAY 54-9085; Biological Markers; Blood; Blood Tests; Blood specimen; Case-Control Studies; Cessation of life; Clear Cell; Clinical; Clinical Trials; Cohort Studies; Collection; Cyst; Data; Diagnosis; Disease; Disease-Free Survival; Eastern Cooperative Oncology Group; Enrollment; European; Excision; Future; Gene Expression Profile; Goals; Histologic; Immunoglobulins; Immunotherapy; Individual; Injury to Kidney; Integral Membrane Protein; International; International Agency for Research on Cancer; Kidney Neoplasms; Lead; Localized Disease; Malignant Neoplasms; Measures; Medical center; Metastatic Renal Cell Cancer; Monitor; Mucins; Nephrectomy; Operative Surgical Procedures; Outcome; Papillary; Pathologic; Pathology; Patients; Phase; Phase III Clinical Trials; Plasma; Prognosis; Prognostic Factor; Prognostic Marker; RNA; Randomized; Recurrence; Renal Cell Carcinoma; Renal Mass; Resected; Retrospective cohort; Risk; Risk Assessment; Sampling; T-Lymphocyte; Testing; Time; Validation; Work; blood-based biomarker; checkpoint therapy; circulating biomarkers; clinical prognostic; cohort; diagnostic biomarker; high risk; immune checkpoint; immunoregulation; improved; mortality; outcome prediction; patient population; predict clinical outcome; prognostic; prospective; rat KIM-1 protein; relapse prediction; relapse risk; risk stratification; targeted treatment; treatment response; tumor

Project Summary While there are many treatment options for patients with metastatic RCC, it is still a deadly disease with considerable mortality. RCC can be much more effectively treated if it is detected early when it is amenable to surgery. To date there is no biomarker for RCC. Additionally, A specific and sensitive circulating biomarker could not only help detect this cancer earlier but could also aid in the diagnosis and monitoring of disease. This proposal seeks to test the utility of circulating kidney injury molecule-1/ T cell immunoglobulin mucin domain-1 (KIM-1/ TIM-1) as a blood test that can be used to follow patients with small renal masses and with the goal of safely avoiding or delaying surgery. We will also measure KIM1 in patients with resected RCC with the goal of identifying a high-risk patient population most likely to benefit from adjuvant therapy after nephrectomy for localized disease. This proposal will also test KIM-1 as a blood test that can help follow response to therapy for metastatic disease. To prepare for submission our team has spent considerable time and effort in identifying readily available patient samples to answer our questions. In this proposal we are poised and have samples available to address all of these questions. We hope that in the future, prospective trials will test KIM-1 in these settings but at this time, rigorous testing in these retrospective cohorts will provide the groundwork for these future studies.

项目总结